1. An evaluation of different methods to study the association of proprotein convertase subtilisin-kexin type 9 to lipoproteins. (August 2021) Authors: Canclini, L.; Malvandi, A.M.; Uboldi, P.; Zampoleri, V.; Baragetti, A.; Grigore, L.; Catapano, A.L. Journal: Atherosclerosis Issue: Volume 331(2021) Page Start: e139 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Optimizing the method of plasma lipoprotein isolation for elucidating their differential association to proprotein convertase subtilisin/kexin 9 (PCSK9). (December 2020) Authors: Canclini, L.; Malvandi, A.M.; Uboldi, P.; Zampoleri, V.; Bellosta, S.; Baragetti, A.; Grigore, L.; Zambon, A.; Catapano, A.L. Journal: Atherosclerosis Issue: Volume 315(2020) Page Start: e161 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. PCSK9 association with LDL: Effects of anti-PCSK9 mAbs therapy. (August 2022) Authors: Canclini, L.; Baragetti, A.; Jabnati, N.; Malvandi, A.M.; Grigore, L.; Catapano, A.L. Journal: Atherosclerosis Issue: Volume 355(2022) Page Start: 216 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Proprotein convertase subtilisin/kexin type 9 (PCSK9) association to LDL in patients treated with anti-PCSK9 monoclonal antibodies. (August 2021) Authors: Canclini, L.; Jabnati, N.; Malvandi, A.M.; Baragetti, A.; Grigore, L.; Catapano, A.L. Journal: Atherosclerosis Issue: Volume 331(2021) Page Start: e139 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗